BCPC · Balchem Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · BCPC

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.04B	$953.68M	$922.44M	$942.36M	$799.02M	$703.64M
Cost of Revenue	$666.53M	$617.48M	$620.38M	$661.91M	$555.85M	$479.75M
Gross Profit	$370.63M	$336.21M	$302.06M	$280.45M	$243.17M	$223.90M
R&D	$18.51M	$16.79M	$15.05M	$12.19M	$13.52M	$10.33M
SG&A	$67.42M	$67.59M	$53.42M	$55.66M	$41.73M	$43.79M
Total Operating Expenses	$161.31M	$153.30M	$142.86M	$135.26M	$115.67M	$112.75M
D&A	$45.69M	$47.97M	$54.94M	$51.85M	$48.88M	$51.28M
Operating Income	$209.33M	$182.91M	$159.19M	$145.19M	$127.50M	$111.15M
Interest Expense	-	-	-	-	-	-
Income Tax	$44.19M	$37.98M	$28.72M	$28.38M	$29.13M	$21.79M
Net Income	$154.84M	$128.47M	$108.54M	$105.37M	$96.10M	$84.62M
EPS - Basic	$4.80	$3.97	$3.38	$3.29	$2.98	$2.63
EPS - Diluted	$4.75	$3.93	$3.35	$3.25	$2.94	$2.60

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$74.57M	$49.52M	$64.45M	$66.56M	$103.24M	$84.57M
Accounts Receivable	$143.60M	$119.66M	$125.28M	$131.58M	$117.41M	$98.21M
Inventory	$131.45M	$130.80M	$109.52M	$119.67M	$91.06M	$70.62M
Accounts Payable	$60.42M	$54.74M	$55.50M	$57.32M	$56.24M	$23.74M
Current Assets	$365.61M	$313.77M	$314.24M	$335.80M	$322.23M	$266.89M
Total Assets	$1.69B	$1.58B	$1.60B	$1.62B	$1.20B	$1.17B
Current Liabilities	$176.38M	$157.69M	$148.49M	$140.04M	$143.80M	$94.43M
Long-term Debt	-	-	-	-	-	-
Total Liabilities	$428.84M	$425.46M	$543.23M	$686.23M	$322.31M	$337.61M
Stockholders' Equity	$1.26B	$1.15B	$1.05B	$938.28M	$877.01M	$828.23M
Retained Earnings	$1.12B	$997.49M	$897.49M	$814.49M	$732.14M	$656.74M

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$216.56M	$182.00M	$183.76M	$138.54M	$160.51M	$150.49M
Investing Cash Flow	($43.89M)	($59.74M)	($34.81M)	($416.01M)	($35.30M)	($34.59M)
Financing Cash Flow	($152.81M)	($133.81M)	($153.32M)	$246.68M	($102.18M)	($101.16M)
CapEx	-	-	-	$49.09M	$36.14M	$32.08M
Free Cash Flow	-	-	-	$89.45M	$124.37M	$118.41M

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	35.7%	35.3%	32.7%	29.8%	30.4%	31.8%
Operating margin	20.2%	19.2%	17.3%	15.4%	16.0%	15.8%
EBITDA margin	24.6%	24.2%	23.2%	20.9%	22.1%	23.1%
Net margin	14.9%	13.5%	11.8%	11.2%	12.0%	12.0%
Free cash flow margin	-	-	-	9.5%	15.6%	16.8%
FCF / Net income	-	-	-	0.85	1.29	1.40
R&D / Revenue	1.8%	1.8%	1.6%	1.3%	1.7%	1.5%
SG&A / Revenue	6.5%	7.1%	5.8%	5.9%	5.2%	6.2%
Effective tax rate	22.2%	22.8%	20.9%	21.2%	23.3%	20.5%
Return on assets	9.2%	8.2%	6.8%	6.5%	8.0%	7.3%
Return on equity	12.3%	11.2%	10.3%	11.2%	11.0%	10.2%
Return on invested capital	-	-	-	-	-	-
Liquidity
Current ratio	2.07	1.99	2.12	2.40	2.24	2.83
Quick ratio	1.33	1.16	1.38	1.54	1.61	2.08
Cash ratio	0.42	0.31	0.43	0.48	0.72	0.90
Leverage
Debt / Equity	-	-	-	-	-	-
Debt / Assets	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-	-	-	-	-	-
Equity multiplier	1.34	1.37	1.52	1.73	1.37	1.41
Liabilities / Assets	0.25	0.27	0.34	0.42	0.27	0.29
Efficiency
Asset turnover	0.62	0.61	0.58	0.58	0.67	0.60
Inventory turnover	5.07	4.72	5.66	5.53	6.10	6.79
Days sales outstanding	51d	46d	50d	51d	54d	51d
Days inventory outstanding	72d	77d	64d	66d	60d	54d
Days payable outstanding	33d	32d	33d	32d	37d	18d
Cash conversion cycle	89d	91d	81d	85d	76d	87d
Valuation
P / E	32.3x	41.5x	44.4x	37.6x	57.3x	44.3x
P / B	4.0x	4.6x	4.6x	4.2x	6.3x	4.5x
P / S	4.8x	5.6x	5.2x	4.2x	6.9x	5.3x
EV / EBITDA	19.3x	22.9x	22.2x	19.7x	30.6x	22.5x
Growth
Revenue growth (YoY)	8.8%	3.4%	-2.1%	17.9%	13.6%	9.3%
Revenue CAGR (3y)	3.2%	6.1%	9.4%	13.5%	7.5%	5.8%
Revenue CAGR (5y)	8.1%	8.2%	7.5%	9.6%	7.6%	5.0%
Gross profit growth (YoY)	10.2%	11.3%	7.7%	15.3%	8.6%	5.9%
Operating income growth (YoY)	14.4%	14.9%	9.6%	13.9%	14.7%	8.4%
Net income growth (YoY)	20.5%	18.4%	3.0%	9.6%	13.6%	6.2%
EPS growth (YoY)	20.9%	17.3%	3.1%	10.5%	13.1%	6.1%
EPS CAGR (3y)	13.5%	10.2%	8.8%	9.9%	6.7%	-2.3%
EPS CAGR (5y)	12.8%	9.9%	6.7%	3.1%	10.9%	6.6%
FCF growth (YoY)	-	-	-	-28.1%	5.0%	20.0%
FCF CAGR (5y)	-	-	-	2.2%	8.0%	13.6%
Book value growth (YoY)	9.3%	9.1%	12.3%	7.0%	5.9%	11.4%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$1.03B total

Human Nutrition And Health$659.39M · 63.9%

Animal Nutrition And Health$230.85M · 22.4%

Specialty Products$140.98M · 13.7%

Product / service

$1.04B total

Product Sales$1.04B · 99.8%

Royalty$1.89M · 0.2%

Geographic

$1.04B total

US$759.45M · 73.2%

Non Us$277.71M · 26.8%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

2.87

Grey zone

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

8/9

Strong

✓Net income positive
✓Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✓Current ratio improved
✓No share dilution
✓Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Chemicals & Allied Products

Company	Revenue (last FY)	Net margin	ROE
FMC	$3.47B	-64.6%	-108.1%
CC	$5.81B	-6.6%	-154.4%
OLN	$6.78B	-1.5%	-5.5%
NGVT	$1.17B	-14.3%	-562.6%
IOSP	$1.78B	6.6%	8.8%

Comparing BALCHEM CORP against the 5 most active filers in the same SIC group.

Dividends

$0.96/share trailing 12 months · +10.3% YoY

Ex-date	Per share
Dec 23, 2025	$0.9600
Dec 26, 2024	$0.8700
Dec 26, 2023	$0.7900
Dec 23, 2022	$0.7100
Dec 27, 2021	$0.6400
Dec 24, 2020	$0.5800
Dec 27, 2019	$0.5200
Dec 24, 2018	$0.4700
Dec 26, 2017	$0.4200
Dec 22, 2016	$0.3800
Dec 23, 2015	$0.3400
Dec 24, 2014	$0.3000
Dec 19, 2013	$0.2600
Dec 12, 2012	$0.2200
Dec 12, 2011	$0.1800
Dec 17, 2010	$0.1500
Dec 28, 2009	$0.0733
Dec 18, 2008	$0.0733
Dec 18, 2007	$0.0733
Dec 27, 2006	$0.0400
Dec 28, 2005	$0.0267
Dec 28, 2004	$0.0178
Dec 24, 2003	$0.0158
Dec 23, 2002	$0.0158